Risedronate in the treatment of Murine Chagas' disease

Area of Science:

• Pharmacology
• Infectious Diseases
• Immunology

Background:

• Chagas' disease, caused by Trypanosoma cruzi, remains a significant global health concern.
• Current treatments for Chagas' disease have limitations and side effects.
• Bisphosphonates are a class of drugs primarily used for bone diseases.

Purpose of the Study:

• To evaluate the efficacy of risedronate, a bisphosphonate, as a potential therapeutic agent against Trypanosoma cruzi infection in vivo.
• To assess the impact of risedronate on mortality, myocardial pathology, and cardiac remodeling in experimental Chagas' disease models.

Main Methods:

• CD-1 mice infected with the Brazil strain of Trypanosoma cruzi were treated with subcutaneous injections of risedronate.
• C57BL/6 mice infected with the Tulahuen strain of Trypanosoma cruzi were also treated with risedronate.
• Mortality rates, myocardial pathology, and right ventricular dilation were assessed in treated and control groups.

Main Results:

• Risedronate treatment led to a significant reduction in mortality in CD-1 mice infected with the Brazil strain.
• However, risedronate did not alter myocardial pathology or right ventricular dilation in these mice.
• No significant changes in mortality were observed in C57BL/6 mice infected with the Tulahuen strain.

Conclusions:

• Bisphosphonates demonstrate in vivo activity against Trypanosoma cruzi.
• Imaging and pathological studies are valuable adjuncts for evaluating therapeutic compounds in experimental Chagas' disease.
• The use of different strains of Trypanosoma cruzi is crucial for comprehensive drug evaluation.